Centogene' headquarters in Rostock, Germany, © Centogene NV

Multi-omics diagnostics specialist Centogene NV has received €30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.

Astraveus CEO Jérémie Laurant. © Astraveus

French cell and gene therapy manufacturing specialist Astraveus SAS had raises €16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.

Deutsche Börse AG/BIOCOM AG

Breaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG.

@ nattanan23/pixabay.com

Carbios SAS has announced a capital increase of around €122m that may grow up  to €141m.

@Veeva Systems

This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries.

© Santhera Pharmaceuticals

Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.

Clinical development of Bone Therapeutics' lead asset, the bone forming cell therapy ALLOB, will be discontinued. © Pixabay.com/virnuls

BioSenic SA has  suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.

EpiTcer platform. Neoantigen-loaded beads are phagocytised by DCs and present antigens to T-cells which in turn are activated. © NEOGAP Therapeutics

Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.

Hantavirus. © CDC/Cynthia Goldsmith

An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.

© Syncona

Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.